Introduction Anti-tumour necrosis factor (anti-TNF) medications have never been compared in a direct fashion under real-world circumstances. The purpose of this study was to compare healthcare utilisation and costs using insurance data for patients with Crohn's disease (CD) who newly initiated anti-TNF therapy with adalimumab (ADA) or infliximab (IFX).
Methods Patients with ≥2 diagnoses of CD (ICD-9-CM: 555.XX) who initiated ADA or IFX therapy between January 2000 and March 2009 were identified from the Medstat MarketScan database. Patients had to be continuously enrolled at least 6 months before and after anti-TNF initiation. Patients with prior biologic therapy (ie, anti-TNF or natalizumab) or colitis (ICD-9-CM: 556.x) were excluded. ADA and IFX groups were matched 1:1 using a propensity score stratified by age, residence, inpatient visit utilisation and steroid use at baseline. The primary endpoint was 6-month direct cost of healthcare. The secondary endpoints compared healthcare utilisation between groups.
Results After propensity matching, demographic, clinical and healthcare utilisation characteristics were similar between the ADA (n=623) and IFX (n=623) groups at baseline. During the 6-month interval following anti-TNF initiation, healthcare costs were significantly lower for ADA compared with IFX therapy (table 1).
|All-Cause, ADA (n=623)||All-Cause, IFX (n=623)||CD-Relateda, ADA (n=623)||CD-Relateda, IFX (n=623)|
|Anti-TNF drug costs||–||–||10 709||12 401|
|Other prescription drug costs||1334b||1639||546||857|
|Total medical service–related costs||6842b||10 316||5199b||9059|
|Total healthcare costs (costs excluding anti-TNF agents)||18 885b (8176b)||24 355 (11 955)||16 454b (5745b)||22 316 (9916)|
Both all-cause and CD-related hospitalisation decreased for both ADA and IFX groups (not shown). Emergency department (ED) use and hospitalisation in the 6-month follow-up period were similar between groups.
Conclusion In this real-world analysis of patients with CD who newly initiated with ADA or IFX, ADA-treated patients had significantly lower healthcare costs. Hospitalisation and ED utilisation were similar between groups.
- Crohn's disease
- healthcare costs
- TNF-alpha inhibitors
Statistics from Altmetric.com
Competing interests D. Sussman: None Declared, N. Kubiliun: None Declared, J. Chao Shareholder with: Abbott, Employee of: Abbott, P. Mulani Shareholder with: Abbott, Employee of: Abbott, C. Gillis Shareholder with: Abbott, Employee of: Abbott, M. Yang Shareholder with: Abbott, Employee of: Abbott, M. Lu Employee of: Analysis Group; under contract with Abb., M. Abreu Consultant for: Abbott, Amgen, Elan, Opson, Prometheus, Salix, UCB
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.